

SWISS BIOTECH SUCCESS STORY



Pioneered T-cell based vaccines for major infectious diseases

Approach centered on exploiting a novel, proprietary and highly potent, replication-incompetent adenovirus vectors

A ground-breaking approach which overcame the major limitation of first-generation vectors, opening the door to the development of important new vaccines

Spin out of Merck Laboratories' Research Center in Rome in 2007 by co-founding investors Life Science Partners (LSP) and BioMedInvest

Company initially set up as a holding in Basel, with laboratories in Rome and Naples

May 2013: GlaxoSmithKline acquires Okairos to strengthen vaccine platform



THE FOUNDING TEAM



Riccardo Cortese
Co-founder & CEO



Alfredo Nicosia
Co-founder & CSO



Stefano Colloca
Senior Director Vector Development



Antonella Folgori
Director of Immunology



SUPPORT

US National Institutes of Health

European Union

The Medical Research Council

Bill and Melinda Gates Foundation




BILL & MELINDA GATES foundation








KNOWLEDGE

Strong patent estate in the field of non-replicating adenoviruses of non-human primates and cell lines for the production of virus



INDICATIONS

Genetic vaccines for both prophylactic and therapeutic applications with focus on hepatitis C, malaria, HIV, respiratory syncytial virus and influenza



PIPELINE

Focus on genetic vaccines against a range of infectious diseases



Vaccines also developed for malaria and Ebola



SUCCESS CATEGORIES

- ★ New technology
- ★ Important IP, innovative deal-making, acquisition
- ★ Swiss-based company/institution
- ★ Other aspect with a direct link to Switzerland